AI Insight
Atopic dermatitis is a highly burdensome inflammatory skin disease that significantly impacts quality of life, sleep, mental health, and healthcare utilization globally. While recent therapeutic advances including biologics targeting type 2 inflammation and oral JAK inhibitors have improved treatment options, a substantial proportion of patients with moderate-to-severe disease still lack durable disease control or discontinue treatment due to loss of response, tolerability, or safety concerns.
Why it matters
This commentary highlights a critical unmet medical need in dermatology, indicating that despite recent therapeutic progress, current treatments remain inadequate for many patients with atopic dermatitis. The recognition of this treatment gap underscores the importance of developing novel therapeutic approaches, such as regulatory T cell expansion, to achieve better long-term disease management.
Understand the Science
Atopic dermatitis remains one of the most burdensome inflammatory skin diseases worldwide, with a substantial effect on quality of life, sleep, mental health, and health-care use. Its population-level effect has been highlighted by the Global Burden of Disease Study analyses, in which atopic dermatitis ranks among the leading skin diseases by disability-adjusted life-years.1 Over the past decade, treatment has changed markedly. Biologics targeting type 2 inflammation and oral Janus kinase (JAK) inhibitors have expanded the therapeutic armamentarium, yet a relevant proportion of patients with moderate-to-severe disease still do not have durable disease control, lose response, or discontinue treatment because of tolerability or safety concerns.
Source: [Comment] Expanding regulatory T cells to treat atopic dermatitis